GSK, SK Bioscience start late-stage trial of Covid vaccine

GSK, SK Bioscience start late-stage trial of Covid vaccine

 

GlaxoSmithKline (GSK) and South Korean pharmaceutical firm SK Bioscience have started a Phase 3 trial of their Covid-19 vaccine combination.

 

GSK told the stock market on Tuesday that; the advance follows “positive” interim results in the Phase 1 and 2 studies.

 

It said the partners are now aiming for global supply through the Covax facility in the first half of 2022; subject to data and regulatory reviews.

 

Thomas Breuer, chief global health officer, GSK, said, “While many countries have made good progress with vaccination; there remains a need for accessible and affordable Covid-19 vaccines to ensure equitable access and to protect people across the world.

ALSO READ: Sanofi, GSK kick off Phase III trial for COVID-19 shot

However, “we are pleased to contribute with GSK’s pandemic adjuvant; and also to be working with SK; to deliver the vaccine at scale via Covax if it is approved.”

 

The late-stage trial will enrol around 4,000 participants from a range of countries to evaluate the vaccine candidate’s safety as well as immunogenicity compared with the Oxford/AstraZeneca vaccine.

 

GSK said the study will be one of the first global late-stage trials to compare two different vaccine candidates.

 

SK Bioscience chief executive Jaeyong Ahn said: “We are grateful that we were able to advance to the Phase 3 study with the unprecedented support of global initiatives; including GSK; Coalition for Epidemic Preparedness Initiative; and also the Bill & Melinda Gates Foundation.

 

“Taking this important step towards overcoming the global pandemic situation; SK as well as GSK will bring our technical expertise together for the development of an adjuvanted protein-based vaccine candidate, GBP510.

About The Author

Osigweh Lilian Oluchi is a graduate of the University of Lagos where she obtained a B.A (Hons) in English, Masters in Public and International affairs (MPIA). Currently works with 1stnews as a Database Manager / Writer. [email protected]

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *